About Servier Symphogen
Servier Symphogen is a company based in Ballerup (Denmark) founded in 2000 was acquired by Servier in April 2020. It operates as a Professional Services. Servier Symphogen has raised $671.45 million across 15 funding rounds from investors including Takeda Pharmaceuticals, HHS and Genentech. The company has 103 employees as of December 31, 2021. Servier Symphogen offers products and services including Antibody Therapeutics. Servier Symphogen operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Ballerup, Denmark
- Employees 103 as on 31 Dec, 2021
- Stage Minicorn
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Servier Symphogen A/S
-
Annual Revenue
$73.72 M (USD)308as on Sep 30, 2021
-
Net Profit
$13.95 M (USD)142as on Sep 30, 2021
-
EBITDA
-
Total Equity Funding
$671.45 M (USD)
in 15 rounds
-
Latest Funding Round
$58.84 M (USD), Series F
May 29, 2019
-
Investors
Takeda Pharmaceuticals
& 11 more
-
Employee Count
103
as on Dec 31, 2021
-
Acquired by
Servier
(Apr 03, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Servier Symphogen
Servier Symphogen offers a comprehensive portfolio of products and services, including Antibody Therapeutics. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Antibody therapeutics are developed for cancer treatment solutions.
Unlock access to complete
Unlock access to complete
Funding Insights of Servier Symphogen
Servier Symphogen has successfully raised a total of $671.45M across 15 strategic funding rounds. The most recent funding activity was a Series F round of $58.84 million completed in May 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 15
- Last Round Series F — $58.8M
-
First Round
First Round
(05 May 2000)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2019 | Amount | Series F - Servier Symphogen | Valuation |
investors |
|
| Nov, 2017 | Amount | Series F - Servier Symphogen | Valuation | Genentech |
|
| Oct, 2015 | Amount | Series F - Servier Symphogen | Valuation | PKA , Novo Holdings |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Servier Symphogen
Servier Symphogen has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Takeda Pharmaceuticals, HHS and Genentech. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Founded Year | Domain | Location | |
|
Growth-stage healthcare companies are invested in by EW Healthcare Partners.
|
Founded Year | Domain | Location | |
|
Private equity and venture captial firm focused on healthcare sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Servier Symphogen
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Servier Symphogen
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Servier Symphogen Comparisons
Competitors of Servier Symphogen
Servier Symphogen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Servier Symphogen
Frequently Asked Questions about Servier Symphogen
When was Servier Symphogen founded?
Servier Symphogen was founded in 2000.
Where is Servier Symphogen located?
Servier Symphogen is headquartered in Ballerup, Denmark.
Who is the current CEO of Servier Symphogen?
Martin Olin is the current CEO of Servier Symphogen.
Is Servier Symphogen a funded company?
Servier Symphogen is a funded company, having raised a total of $671.45M across 15 funding rounds to date. The company's 1st funding round was a Series F of $76.62M, raised on May 05, 2000.
How many employees does Servier Symphogen have?
As of Dec 31, 2021, the latest employee count at Servier Symphogen is 103.
What is the annual revenue of Servier Symphogen?
Annual revenue of Servier Symphogen is $73.72M as on Sep 30, 2021.
What does Servier Symphogen do?
Servier Symphogen is recognized as the Antibody Center of Excellence within the Servier Group. The company is primarily engaged in oncology and immune oncology sectors. A highly efficient antibody discovery and research platform is utilized, supported by comprehensive early development capabilities. Unique functionalities in antibodies are delivered, offering potential for best or first-in-class treatments as combination or monotherapy. Combination therapies, central to future cancer treatments, are well-suited to the companys approach and capabilities. Scientific innovation is emphasized as the core of advancing cancer therapies.
Who are the top competitors of Servier Symphogen?
Servier Symphogen's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
What products or services does Servier Symphogen offer?
Servier Symphogen offers Antibody Therapeutics.
Who are Servier Symphogen's investors?
Servier Symphogen has 12 investors. Key investors include Takeda Pharmaceuticals, HHS, Genentech, Servier, and Danica Pension.
What is Servier Symphogen's valuation?
The valuation of Servier Symphogen is $281.31M as of May 2019.